hydroxylysine and Breast-Neoplasms

Topics: Bone Neoplasms; Breast Neoplasms; Collagen; Colorimetry; Female; Humans; Hydroxylysine; Hydroxyproline; Lung Neoplasms; Male; Multiple Myeloma; Neoplasms; Prostatic Neoplasms

A study was carried out to assess the best use of biochemical bone markers to exclude metastases in patients with breast cancer. Urinary galactosyl-hydroxylysine and serum alkaline phosphatase were used to monitor bone resorption and deposition, respectively. Hydroxyproline was also measured. In a selected population of patients, possibly affected by metastases on the basis of scintigraphic examination, which is highly sensitive but poorly specific, we assessed the efficiency of the markers by a double statistical analysis. In this group, the only marker able to predict metastases was galactosyl-hydroxylysine.

Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Hydroxylysine; Hydroxyproline

We measured the urinary excretion of galactosyl-hydroxylysine (GH) and hydroxyproline in two groups of women with breast cancer, with (M+, n = 24) and without (Mo, n = 30) clinical, scintigraphic, or radiological evidence of bone metastases. Both these compounds are excreted in larger amounts in the M+ group than in the Mo patients. However, GH, which is a specific marker for bone collagen, provides better predictivity for bone metastases than does hydroxyproline: 92% sensitivity and 90% specificity vs 74% and 79%, respectively, for hydroxyproline.

Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diagnostic Errors; Female; Humans; Hydroxylysine; Monitoring, Physiologic; Neoplasm Metastasis; Risk